AN ACT

To enact R.S. 46:153.3(C)(2), relative to Medicaid coverage for prescription drugs; to provide for prescribed drugs used to treat schizophrenia and schizotypal or delusion disorders; and to provide for related matters.

Be it enacted by the Legislature of Louisiana:

Section 1. R.S. 46:153.3(C)(2) is hereby enacted to read as follows:

§153.3. Medical vendor reimbursements; allowable restrictions; peer-based prescribing and dispensing practice patterns; Medicaid Pharmaceutical and Therapeutics Committee

  *  *  *

C.

  *  *  *

(2) The department shall not restrict by prior authorization any prescription drug prescribed to an adult patient and determined by a prescribing practitioner licensed by the state to be medically necessary for the treatment and prevention of schizophrenia and schizotypal or any delusion disorders, including but not limited to first episode psychosis, if either of the following conditions are met and the request is in accordance with federal

Coding: Words which are struck through are deletions from existing law; words in **boldface type and underscored** are additions.
requirements:

(a) During the preceding year, the patient was prescribed and unsuccessfully treated with a preferred drug, whether a brand or generic drug.

(b) The patient has previously been prescribed and obtained prior authorization for the nonpreferred prescribed drug.

* * *

The original instrument was prepared by Brandi Cannon. The following digest, which does not constitute a part of the legislative instrument, was prepared by Cheryl Serrett.

DIGEST
SB 77 Reengrossed 2022 Regular Session Luneau

Present law provides for prescription drug coverage in the Louisiana Medicaid program, including a preferred drug list established in conjunction with a prior approval process.

Proposed law retains present law but prohibits any restriction by prior authorization of a prescription drug prescribed to an adult patient and determined by a licensed prescriber to be medically necessary for the treatment and prevention of schizophrenia and schizotypal or any delusion disorders if, during the preceding year, the patient was unsuccessfully treated with the preferred drug or the patient has previously been prescribed and obtained prior authorization for the nonpreferred drug and the request is in accordance with federal requirements.

Effective August 1, 2022.

(Adds R.S. 46:153.3(C)(2))

Summary of Amendments Adopted by Senate

Committee Amendments Proposed by Senate Committee on Health and Welfare to the original bill
1. Narrows the scope of the bill to drugs that treat schizophrenia and schizotypal or delusion disorders.
2. Makes technical changes.

Senate Floor Amendments to engrossed bill
1. Changes number of conditions required for a nonpreferred drug to be approved.
2. Clarifies the requests must be in accordance with federal requirements.
3. Removes time requirements relative to prior treatment usage.
4. Makes technical changes.